Targeting cancer micrometastases with monoclonal antibodies: a binding-site barrier. - Wikidata - awgldk - TriplyDB

Targeting cancer micrometastases with monoclonal antibodies: a binding-site barrier.

Targeting cancer micrometastases with monoclonal antibodies: a binding-site barrier.

http://www.wikidata.org/entity/Q33944050

about

Affinity and avidity in antibody-based tumor targeting Site-specific functionalization of proteins and their applications to therapeutic antibodies The development of immunoconjugates for targeted cancer therapy Current Multistage Drug Delivery Systems Based on the Tumor Microenvironment.Pulsed high intensity focused ultrasound increases penetration and therapeutic efficacy of monoclonal antibodies in murine xenograft tumors.The Interactions between L-tyrosine based nanoparticles decorated with folic acid and cervical cancer cells under physiological flow Engineering lipid vesicles of enhanced intratumoral transport capabilities: correlating liposome characteristics with penetration into human prostate tumor spheroids.The distribution of the therapeutic monoclonal antibodies cetuximab and trastuzumab within solid tumors Effect of antigen turnover rate and expression level on antibody penetration into tumor spheroids.Design and applications of bispecific heterodimers: molecular imaging and beyond Semiquantitative assessment of the microdistribution of fluorescence-labeled monoclonal antibody in small peritoneal disseminations of ovarian cancer Evaluation of anti-podoplanin rat monoclonal antibody NZ-1 for targeting malignant gliomas Improved modeling of in vivo kinetics of slowly diffusing radiotracers for tumor imaging.Safety and biodistribution of 111In-amatuximab in patients with mesothelin expressing cancers using single photon emission computed tomography-computed tomography (SPECT-CT) imaging.Combined-modality radioimmunotherapy: synergistic effect of paclitaxel and additive effect of bevacizumab Differential Toxicity of Antibodies to the Prion Protein.Immunotoxin and Taxol synergy results from a decrease in shed mesothelin levels in the extracellular space of tumors.Stimuli-responsive nanoparticles for targeting the tumor microenvironment.Issues related to targeted delivery of proteins and peptides.Nanoscale drug delivery systems for enhanced drug penetration into solid tumors: current progress and opportunities.Nanovehicular intracellular delivery systems.3-D tissue culture systems for the evaluation and optimization of nanoparticle-based drug carriers The Effect of Molecular Weight, PK, and Valency on Tumor Biodistribution and Efficacy of Antibody-Based Drugs.Marine Antibody-Drug Conjugates: Design Strategies and Research Progress.Using antibodies to target cancer therapeutics.Antibody Drug Conjugates: Application of Quantitative Pharmacology in Modality Design and Target Selection.Practical theoretic guidance for the design of tumor-targeting agents.Binding and transport of PAMAM-RGD in a tumor spheroid model: the effect of RGD targeting ligand density.Small Molecules for Active Targeting in Cancer.Sweeping lymph node micrometastases off their feet: an engineered model to evaluate natural killer cell mediated therapeutic intervention of circulating tumor cells that disseminate to the lymph nodes.A33 antigen displays persistent surface expression.Tissue engineered tumor models.Intracranial elimination of human glioblastoma brain tumors in nude rats using the bispecific ligand-directed toxin, DTEGF13 and convection enhanced delivery.Recombinant Immunotoxin Therapy of Glioblastoma: Smart Design, Key Findings, and Specific Challenges.Factors determining antibody distribution in tumors.Targeted photodestruction of human colon cancer cells using charged 17.1A chlorin e6 immunoconjugates.Molecular imaging using an anti-human tissue factor monoclonal antibody in an orthotopic glioma xenograft model Recombinant Immunotoxin Therapy of Solid Tumors: Challenges and Strategies.A model for optimizing delivery of targeted radionuclide therapies into resection cavity margins for the treatment of primary brain cancers.Chemically Defined Antibody- and Small Molecule-Drug Conjugates for in Vivo Tumor Targeting Applications: A Comparative Analysis.

P2860

Q24613552-AB888810-5CA7-4D57-A8D2-A7680A9FD9A8 Q26830699-64A91757-5CF9-49A2-BE31-4A2906E289B6 Q27021990-0B474479-BD3F-4E99-8FFD-B6A3DEAB3E4E Q30362001-97992B4C-CE68-4C80-B7BB-AC9F70073B10 Q30426788-F37A15A2-EE5C-416F-A916-9FB93D1A3818 Q30529631-1D03129D-39BB-4D31-B7BE-A020F004BD93 Q33224253-3EBEE9E9-8B49-4CB5-9106-B425833A417E Q33595085-365BD1F4-A101-4F3F-9E98-74B4831D6A8A Q33698791-5F8BF926-9568-480C-B4BC-EC74B5114E05 Q33732587-55CAF463-AE32-4977-8A1E-26EAD16B4B0B Q33764520-4C73DCED-79EF-4529-9177-FF725C103EA0 Q34160649-87CFEBF9-35AC-4AED-A751-F4C9C3650A39 Q35101117-B84CFE0F-94AE-4174-9DC0-887C0835487F Q35552059-4914DB99-EDCE-43FD-96BB-9DF2607A28E6 Q35842769-6FFC8744-30CE-4239-8B53-562203F6F255 Q35907379-954B86B5-C107-43E2-AC2E-D692E9114018 Q36089304-11D45F3B-CE0A-4BA3-8BF9-4E52F2824DC2 Q36307519-5853C11C-ADD7-4B19-937A-4584F0A25821 Q36616311-08B8542E-EF75-410E-8090-A08EFA8BFC1B Q36803827-F93BBFCA-5BC0-463C-8D28-8798AB516E65 Q37058812-E5B68709-F653-444E-A4DF-6662FA916C5B Q37120582-9DDEBBCB-BF60-44D5-BB69-2F0BBD65A7A9 Q37236019-756C85FD-734B-444E-9437-861802121323 Q37628646-E827FAFD-7FE0-47E3-8485-3EE63D99BA9D Q38014920-8E133BB3-3139-4056-B15D-50A6E6025E19 Q38453769-E6582951-4183-4F92-872B-679D995C00A8 Q38644304-BBC0C76A-BACD-4220-A7B4-3BEC4FE576F9 Q38708174-3D650566-2D78-4637-A9EC-9975849B6D04 Q38780383-E4BE5AD5-014D-40A6-8AAB-6071F4477F26 Q39112305-6C0E43B3-9A63-460E-81F9-2071F36355E4 Q39543140-DA382CEF-7B93-48FC-A801-F01E6C5C787B Q39702718-4E710356-CFD1-47AE-BF36-35079C9DFC0F Q39839534-219ECE17-4795-42EA-85DA-ABC3721E4D34 Q41022992-23CBC005-B35C-4596-814C-29CBE7FD640C Q41807570-55D047A5-D195-492D-BA1D-1AF020BB427F Q41850842-20BB5CE3-62DE-46F5-BB49-D4D9A180E168 Q42364589-08A9C92C-4B24-44A7-9FAB-1C42537D5C15 Q42939121-AD7715B6-3994-4A16-857D-2BEF2BCBA41F Q47400332-FD65D3FE-A017-45F2-8EEA-7EBDF978324B Q48226060-51ABCD22-F726-4D6C-8C2E-9F07BC4D4B1F

P2860

Targeting cancer micrometastases with monoclonal antibodies: a binding-site barrier.

http://www.wikidata.org/entity/Q33944050

description

1995 nî lūn-bûn

@nan

1995 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

1995 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

1995年の論文

@ja

1995年論文

@yue

1995年論文

@zh-hant

1995年論文

@zh-hk

1995年論文

@zh-mo

1995年論文

@zh-tw

1995年论文

@wuu

name

Targeting cancer micrometastases with monoclonal antibodies: a binding-site barrier.

@ast

Targeting cancer micrometastases with monoclonal antibodies: a binding-site barrier.

@en

type

label

Targeting cancer micrometastases with monoclonal antibodies: a binding-site barrier.

@ast

Targeting cancer micrometastases with monoclonal antibodies: a binding-site barrier.

@en

prefLabel

Targeting cancer micrometastases with monoclonal antibodies: a binding-site barrier.

@ast

Targeting cancer micrometastases with monoclonal antibodies: a binding-site barrier.

@en

P1433

Q33944050-84620164-AD1E-4862-9BB6-30A3E7A1E891

P1476

Q33944050-1182C8E3-016D-4817-B2F0-2FED4D7C656B

P2093

Q33944050-0F283D0E-7314-4899-8451-C80D38632FE9

Q33944050-36708CAD-8C71-4B21-8A4F-45E72F7520E1

Q33944050-A10F84C1-D716-437E-A369-1FE2D295A220

Q33944050-A2C89A55-6382-456E-845D-F403A4A92D71

Q33944050-BDD9266B-A726-4160-A45E-DBC1F2D8FD13

Q33944050-BFCFFF3E-5A0C-46F2-83DC-6E1023B7CADD

Q33944050-C780CF62-7F13-4752-A78E-3A1EEAF4C5CC

Q33944050-C94E3F54-B7A8-46AB-ABC1-48FEBFAC66F7

P2860

Q33944050-00F0D7B4-6640-4EF3-9ED6-08239C08F0EE

Q33944050-078596B1-F75C-414E-AAB7-C08F8B40CDB4

Q33944050-13CFB368-6395-45BF-BBC1-B99CFEC11C15

Q33944050-13D6A51E-28E7-4A52-B819-B2B2034F2C22

Q33944050-16C0311F-58C5-4EE5-AF6A-94399A129862

Q33944050-1A90D4A2-2972-40FF-9F4B-BACB8B658C3A

Q33944050-3DEA02C6-7808-486A-886D-51277C17A07A

Q33944050-727034CD-1800-406A-9D37-39AE5BB7C4E5

Q33944050-796C6DD9-7107-44C6-85FD-8D2C0E64E80A

Q33944050-8127080B-CB2D-4711-9A5E-6851918F01E6

P304

Q33944050-F7922AFA-B841-4AC4-A724-8B5AD296A9E3

P31

Q33944050-0BF988E5-C747-49A5-BED2-5EEDE06AE4B2

P356

Q33944050-95A86DD5-7C2F-4C5D-89D2-2EE844A0681D

P407

Q33944050-8CA06991-D006-4A5D-9011-6770DE5D4258

P433

Q33944050-91A7D6CD-5F1F-4656-8314-095E5C73B14F

P478

Q33944050-FC69DB06-67AC-4AD9-BDEB-F8AD746FB35B

P577

Q33944050-A6D31258-D014-49FD-A149-42148997F51D

P5875

Q33944050-9B5F6212-FDCA-4D72-B313-FBD65ACDA017

P698

Q33944050-C54B458E-98B3-4913-A7B1-8C445892CE4A

P921

Q33944050-138FFF2A-ADC9-4EF8-9E5C-21F4A1ED0496

P932

Q33944050-292934ED-2DCA-40B3-A83C-BA42762A3AFD

P356

PNAS.92.19.8999

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Targeting cancer micrometastases with monoclonal antibodies: a binding-site barrier.

@en

P2093

Heya T

http://www.w3.org/2001/XMLSchema#string

Kinuya S

http://www.w3.org/2001/XMLSchema#string

Le N

http://www.w3.org/2001/XMLSchema#string

Neumann RD

http://www.w3.org/2001/XMLSchema#string

Paik CH

http://www.w3.org/2001/XMLSchema#string

Saga T

http://www.w3.org/2001/XMLSchema#string

Sato J

http://www.w3.org/2001/XMLSchema#string

Weinstein JN

http://www.w3.org/2001/XMLSchema#string

P2860

Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures

Preparation of iodine-131 labelled human growth hormone of high specific activity

Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules

Transport of fluid and macromolecules in tumors. I. Role of interstitial pressure and convection.

The pharmacology of monoclonal antibodies.

Pathogenesis of metastatic disease: implications for current therapy and for the development of new therapeutic strategies.

The biology of cancer invasion and metastasis.

Micropharmacology of monoclonal antibodies in solid tumors: direct experimental evidence for a binding site barrier.

The effect of antibody protein dose on the uniformity of tumor distribution of radioantibodies: an autoradiographic study.

An analysis of monoclonal antibody distribution in microscopic tumor nodules: consequences of a "binding site barrier".

P304

8999-9003

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.92.19.8999

http://www.w3.org/2001/XMLSchema#string

P407

P433

19

http://www.w3.org/2001/XMLSchema#string

P478

92

http://www.w3.org/2001/XMLSchema#string

P577

1995-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

15631178

http://www.w3.org/2001/XMLSchema#string

P698

7568060

http://www.w3.org/2001/XMLSchema#string

P921

P932

41095

http://www.w3.org/2001/XMLSchema#string